U.S. physicians report that the majority of their patients on Teva Pharmaceuticals’ Austedo and Neurocrine Biosciences’ Ingrezza achieve some degree of symptom relief, according to findings from REACH Market Research.  

NEWTON, Mass., – January 17, 2024 – Tardive dyskinesia (TD) is a medication-induced neurological disorder which disrupts patients’ quality of life with complications that include: 

  • Tapping or shaking of the fingers and hands 
  • Puckering and frowning of the mouth and darting tongue 
  • Rapid or constant blinking 
  • Movements of the trunk 

According to TD experts interviewed by REACH, most TD patients are well-controlled with one of the two FDA-approved VMAT2 inhibitors. Austedo and Ingrezza are viewed as comparable options due to their similar efficacy, side effect profiles, and now, dosing convenience with the introduction of Austedo extended-release tablets. Consequently, individual physician preference is driven most often by prior experience and familiarity with a drug. 

Psychiatrist, U.S.: “I mean it’s amazing to see what they [VMAT2 inhibitors] can do to people who had suffered for many years and whose lives had been very much destroyed by it [TD].” 

To access REACH’s MarketVue® Report on Tardive Dyskinesia, visit https://reachmr.com or contact us at info@reachmr.com.  

The report indicates that given the success of Austedo and Ingrezza, clinicians do not perceive a high unmet need for novel TD treatments, which is also reflected in the sparse TD pipeline. However, experts say they have observed a rise in prescriptions for dopamine receptor blocking agents beyond use in schizophrenia, expanding to wider use in other conditions: 

  • Major depressive disorder 
  • Bipolar disorder 
  • Gastroparesis 
  • Behavior conditions (e.g., autism) 

This suggests a potential surge in TD cases in the future which underscores the growing demand for efficacious medications that avoid directly inhibiting the dopamine pathway, working to effectively prevent TD. 

Psychiatrist, U.S.: “The future is not treating TD. I think the future is not inducing it… we may solve the problem by just not having drugs that cause the problem to begin with.”  

About MarketVue®   

MarketVue® reports are a rare disease focused, fresh alternative to traditionally long and outdated market research reports. MarketVue® reports cover rare disease epidemiology and key market dynamics based on research from key opinion leader interviews, physician surveys, and secondary data.